Compare BridgeBio Pharma Inc (BBIO) vs Diamondback Energy Inc (FANG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Diamondback Energy Inc — how do they compare? BridgeBio Pharma Inc trades at $82.6 (market cap $16.46B), while Diamondback Energy Inc trades at $188.58 (market cap $53.64B). The key difference: Diamondback Energy Inc is far larger — about 3.3× BridgeBio Pharma Inc's market cap, and Diamondback Energy Inc pays a 2.31% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | FANG | |
|---|---|---|
Market Cap | $16.46B | $53.64B |
Sector | Health | Energy |
52-Week High | $90.17 | $213.69 |
52-Week Low | $44.81 | $134.53 |
Enterprise Value | $18.02B | $67.37B |
Dividend Yield | — | 2.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Diamondback Energy (FANG) trades at $191.6, up 4.48% today, with a bullish technical signal and strong analyst support. The stock shows robust revenue growth, reaching $14.93B in 2025, though net income margins have compressed. Recent earnings beat expectations in Q1 2026, and the company maintains a solid balance sheet with manageable debt levels. A dividend of $1.10 was recently paid, enhancing shareholder returns.
FANG presents a favorable outlook with a consensus price target of $234.50, implying significant upside. However, risks include volatile oil prices, declining profit margins, and execution challenges in a competitive energy sector. The stock's high P/E ratio of 195.51 warrants caution, but strong cash flow and institutional bullishness support a positive investment case for growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →
